Heterologous Hyperimmune Polyclonal Antibodies Against SARS-CoV-2: A Broad Coverage, Affordable, and Scalable Potential Immunotherapy for COVID-19.

Alberto Alape-Giron,Andres Moreira-Soto,Mauricio Arguedas,Hebleen Brenes,Willem Bujan,Eugenia Corrales-Aguilar,Cecilia Diaz, Ann Echeverri,Marietta Flores-Diaz,Aaron Gomez,Andres Hernandez,Maria Herrera,Guillermo Leon,Roman Macaya,Jose Arturo Molina-Mora,Javier Mora,Aarthi Narayanan,Alfredo Sanabria,Andres Sanchez,Laura Sanchez,Alvaro Segura,Eduardo Segura,Daniela Solano, Claudio Soto,Jennifer L. Stynoski,Mariangela Vargas,Mauren Villalta,Jan Felix Drexler,Jose Maria Gutierrez

Frontiers in medicine（2021）

Cited 8|Views23
No score
Key words
heterologous antibodies,passive immunotherapy,COVID-19,SARS-CoV-2,hyperimmune polyclonal antibodies,convalescent plasma,monoclonal antibodies
AI Read Science
Must-Reading Tree
Example
Generate MRT to find the research sequence of this paper
Chat Paper
Summary is being generated by the instructions you defined